Companies: 10,795·Total market cap: $144.5T
GeneDx Holdings Corp.

GeneDx Holdings Corp.

WGSNASDAQHealthcare● Active
$55.65
+$3.85(+7.43%)
Market Cap$1.7B
P/E Ratio
52W High$170.87
52W Low$32.21
Overview

GeneDx Holdings Corp. (WGS) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

wgs · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for GeneDx Holdings Corp. (WGS) measures how much investors pay for each dollar of the company's trailing earnings. WGS's current PE ratio of N/A is calculated by dividing its stock price of $55.65 by its TTM earnings per share of -$2.65.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
45.20x
FY2027 est. EPS $1.23
Based on 4 analysts
EPS (TTM)
-$2.65
TTM · diluted EPS
PEG Ratio
-0.00
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · GeneDx Holdings Corp. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2019 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Medical - Healthcare Information Services · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
GeneDx Holdings Corp.
GeneDx Holdings Corp.You
WGS
$1.7BN/A-$2.65
Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc.
CRNX
$3.5BN/A-$4.95
Hinge Health, Inc.
Hinge Health, Inc.
HNGE
$4.9BN/A-$6.67
Immunovant, Inc.
Immunovant, Inc.
IMVT
$6.3BN/A-$2.77
Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc.
KYMR
$6.1BN/A-$3.69
NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company N.V.
NAMS
$3.6BN/A-$1.78
Option Care Health, Inc.
Option Care Health, Inc.
OPCH
$3.2B24.88x$1.28

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 7 of 7 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-0.78
2024-12-31
FY2024
$-1.94
2023-12-31
FY2023
$-7.23
2022-12-31
FY2022
$-53.63
2021-12-31
FY2021
$-74.93
2020-12-31
FY2020
$-42.89
2019-12-31
FY2019
$-5.28

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for GeneDx Holdings Corp. (WGS) measures how much investors pay for each dollar of the company's trailing earnings. WGS's current PE ratio of N/A is calculated by dividing its stock price of $55.65 by its TTM earnings per share of -$2.65.

PE Ratio = Stock Price ÷ EPS (TTM)
= $55.65 ÷ -$2.65 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

WGS pe ratio · 6 questions

WGS's current PE ratio is N/A as of 2026-06-09, based on a stock price of $55.65 and TTM EPS of -$2.65. Data sourced from Financial Modeling Prep via WGS's SEC 10-K and 10-Q filings.

WGS PE ratioWhat is WGS PE ratioCurrent PE ratio of WGSWGS PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · GeneDx Holdings Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09